You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華仁藥業(300110.SZ):部分產品中選化學藥品省際聯盟帶量聯動採購

格隆匯6月3日丨華仁藥業(300110.SZ)公佈,公司及全資子公司華仁藥業(日照)有限公司近期積極參與了環磷腺苷葡胺等66個化學藥品省際聯盟帶量聯動採購(採購文件編號:SCLM-YP2025-1)的投標工作。根據四川省藥械招標採購服務中心近日公佈的中選結果,公司產品血液濾過置換基礎液、單硝酸異山梨酯氯化鈉注射液及子公司華仁藥業(日照)有限公司產品甘露醇注射液、卡絡磺鈉氯化鈉注射液中選本次帶量聯動採購。

本次中選產品2024年合計銷售收入爲8,561.77萬元,佔公司2024年營業收入總額的6.33%,其中血液濾過置換基礎液2024年銷售收入爲7,898.20萬元,佔公司2024年營業收入總額的5.84%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account